The potent TGF-β antagonist Norrin as a new drug for the treatment of fibrotic diseases and cancer
Human Norrin protein has been originally identified in the art as being a crucial factor in the development of Norrie disease and is thought to be primarily involved in the Wnt signaling pathway. In the present invention, Norrin is
being identified for the first time as a potent TGF-β antagonist/inhibitor. Furthermore, it has surprisingly been found herein that Norrin can be used in the treatment of diseases associated with an increased TGF-β activity level, such as fibrotic diseases and proliferative diseases, resp. cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
